[Analysis of Clinical Efficacy and Influencing Factors of Gemcitabine-L-Asparaginase-Oxaliplatin Chemotherapy Scheme and Radiotherapy for Treatment of Early ENKTL Patients].
To analyse the clinical efficacy and its influencing factors of early ENKTL patients received chemotherapy of gemcitabine-L-asparaginase-oxaliplatin (GELOX) scheme and radiotherapy. The clinical data of 80 cases of early nasal type NK/T cell lymphoma treated during May 2013 to May 2016 were analyzed retrospectively. The earty ENKTL patients were divided into 3 groups: group I (50 cases) with GELOX after chemotherapy combined with radical radiotherapy, group II (16 cases) with GELOX after other chemotherapy combined radical radiotherapy, group III (14 cases) patients only received GELOX chemotherapy. The average cycle of chemotherapy was 3 cycles, and the total dose of irradiation was 50.20± 3.50 Gy/(20-30 times). After the treatment of 80 early ENKTL patients, the CR rate of patients was 67.50% (54/80); the CR rate of patients in I, II, III groups received chemotherapy was 45%, 10%, 18% rate respectively (P=0.029). The 2 years PFS of the 80 paaients was 79%,and 2 year OS rate was 85.00%; the 2 year PFS rate and OS rate in group 1 and 3 were 84% and 92.00%. The 2 year OS rate, PFS rate in group 1 (96%, 84%) were higher than that in group 3 (47%, 40.00%)(P=0.045,0.003) and group II (50%, 45%, P=0.001,0.00); the OS rate and PFS rate in group 2 and 3 were not statistically significant different (P=0.220,0.97). The factors that affect OS and PFS were remission or not remission after chemotherapy. Clinical use of GELOX induction chemotherapy combined with radical radiotherapy in the treatment of early ENKTL can achieve good therapeutic results.